Abstract 75P
Background
Sarcomas of Gastrointestinal tract (GIT) are extremely rare accounting for less than 1% of GI malignancies. These are diverse group of neoplasms with varied histologies. Advancement in molecular and immunohistochemical markers has led to refinements in the description and classification of sarcomas. Majority of available literature regarding sarcomas of GIT is limited to case reports or small case series. Herein, we present one of the largest case series of sarcomas of GIT diagnosed and treated at our institute.
Methods
This is a retrospective study of histologically confirmed cases of sarcomas of GIT registered in our department from 2012 to 2022. The clinical profile, demographics, pathological characteristics and treatment data were obtained from the medical records.
Results
A total of 19 patients were registered in our department. The median age was 48 years (range, 23-69 years). Ten patients (52.6%) were female. The median duration of symptoms was 4 months (range, 2 – 48 months). Stomach was the most common site (n=6), followed by liver (n=4), jejunum (n=3), ileum (n=2), duodenum (n=1), colon (n=1), rectum (n=1) and oesophagus (n=1). Leiomyosarcoma was the predominant histological type observed in 14 (73.7%) patients. All three patients of leiomyosarcoma of liver were unresectable. Thirteen patients (68.4%) underwent surgery. Chemotherapy was given in 14 patients (adjuvant in 8 and palliative in 6 patients, respectively). Adjuvant radiotherapy was given in 6 patients and palliative radiotherapy in 2 patients. Two patients of leiomyosarcoma of liver are on pazopanib. The median follow-up was 16 months. The 3-year and 5-year overall survival was 50.5% and 37.9%, respectively.
Conclusions
Sarcomas of GIT are exceedingly rare neoplasms. Leiomyosarcoma was the most common histological type seen in our patients. Patients who underwent surgery have better outcome. Aggressive multimodality treatment may improve the survival and outcome. Further multicentre study of the biological behaviour and optimal treatment of these rare neoplasms is warranted.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.